BRAF paradox breakers PLX8394, PLX7904 are more effective against BRAFV600Ε CRC cells compared with the BRAF inhibitor PLX4720 and shown by detailed pathway analysis

Targeting Alterations in the RAF–MEK Pathway

(2019) Rona Yaeger et al.   Cancer Discovery

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

(2019) Scott Kopetz et al.   NEW ENGLAND JOURNAL OF MEDICINE

OUP accepted manuscript

(2018)   BIOINFORMATICS

Targeting tumor cell plasticity by combined inhibition of NOTCH and MAPK signaling in colon cancer

(2018) Eva Marina Schmidt et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Current Insights of BRAF Inhibitors in Cancer

(2018) Bogos Agianian et al.   JOURNAL OF MEDICINAL CHEMISTRY

Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway

(2018) Iman W. Achkar et al.   Journal of Translational Medicine

Phase 1/2 precision medicine study of the next-generation BRAF inhibitor PLX8394.

(2018) Filip Janku et al.   JOURNAL OF CLINICAL ONCOLOGY

RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling

(2018) Zhan Yao et al.   NATURE MEDICINE

The Gene Ontology Resource: 20 years and still GOing strong

(2018)   NUCLEIC ACIDS RESEARCH

Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma

(2017) Xian Chan et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Dabrafenib plus trametinib in patients with previously untreated BRAF V600E -mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

(2017) David Planchard et al.   LANCET ONCOLOGY

PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation

(2017) Candani S. A. Tutuka et al.   Molecular Cancer

Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas In Vivo and Ex Vivo

(2017) Edward J. Hartsough et al.   MOLECULAR CANCER THERAPEUTICS

Epidermal growth factor receptor in glioblastoma

(2017) Hongsheng Xu et al.   Oncology Letters

IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis

(2016) Philippos Perimenis et al.   BMC CANCER

An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling

(2016) Zoi Karoulia et al.   CANCER CELL

Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer

(2016) Hisato Kawakami et al.   MOLECULAR CANCER THERAPEUTICS

Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinaseBRAF-mutant lung cancer

(2016) Ross A. Okimoto et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MEK inhibitors block growth of lung tumours with mutations in ataxia–telangiectasia mutated

(2016) Michal Smida et al.   Nature Communications

BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells

(2016) Maria Goulielmaki et al.   Oncotarget

AZD6244 inhibits cisplatin-induced ERK1/2 activation and potentiates cisplatin-associated cytotoxicity in K-ras G12D preclinical models

(2015) Eun Young Kim et al.   CANCER LETTERS

Structural Investigation of B-Raf Paradox Breaker and Inducer Inhibitors

(2015) Rohit Arora et al.   JOURNAL OF MEDICINAL CHEMISTRY

RAF inhibitors that evade paradoxical MAPK pathway activation

(2015) Chao Zhang et al.   NATURE

The Reactome pathway Knowledgebase

(2015) Antonio Fabregat et al.   NUCLEIC ACIDS RESEARCH

Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy

(2015) R Mandal et al.   ONCOGENE

Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma

(2015) Neel M. Fofaria et al.   Oncotarget

PDGFRα up-regulation mediated by Sonic Hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation

(2015) Francesco Sabbatino et al.   Oncotarget

B-Raf Inhibitors Induce Epithelial Differentiation in BRAF-Mutant Colorectal Cancer Cells

(2014) R. Herr et al.   CANCER RESEARCH

Long-term effects of BRAF inhibitors in melanoma treatment: friend or foe?

(2014) Sarah Sloot et al.   EXPERT OPINION ON PHARMACOTHERAPY

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

(2014) Georgina V. Long et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

(2014) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis

(2014) T. J. Parmenter et al.   Cancer Discovery

featureCounts: an efficient general purpose program for assigning sequence reads to genomic features

(2013) Y. Liao et al.   BIOINFORMATICS

Risk Assessment of Esophageal Adenocarcinoma Using  -H2AX Assay

(2013) E. Xu et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Dysregulation and crosstalk of cellular signaling pathways in colon carcinogenesis

(2013) William K.K. Wu et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Tumor adaptation and resistance to RAF inhibitors

(2013) Piro Lito et al.   NATURE MEDICINE

Notch inhibitors for cancer treatment

(2013) Ingrid Espinoza et al.   PHARMACOLOGY & THERAPEUTICS

STAR: ultrafast universal RNA-seq aligner

(2012) Alexander Dobin et al.   BIOINFORMATICS

A phase II study of RO4929097 in metastatic colorectal cancer

(2012) Jonathan R. Strosberg et al.   EUROPEAN JOURNAL OF CANCER

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

(2012) Anirudh Prahallad et al.   NATURE

Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation

(2012) Davis J. McCarthy et al.   NUCLEIC ACIDS RESEARCH

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

(2012) Ryan B. Corcoran et al.   Cancer Discovery

Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer

(2011) H. Yang et al.   CANCER RESEARCH

Phosphorylated H2Ax is not an unambiguous marker for DNA double-strand breaks

(2011) James E. Cleaver et al.   CELL CYCLE

Selective BRAFV600E Inhibitor PLX4720, Requires TRAIL Assistance to Overcome Oncogenic PIK3CA Resistance

(2011) Eftychia Oikonomou et al.   PLoS One

DNA-PKcs plays a dominant role in the regulation of H2AX phosphorylation in response to DNA damage and cell cycle progression

(2010) Jing An et al.   BMC MOLECULAR BIOLOGY

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

(2010) Poulikos I. Poulikakos et al.   NATURE

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

(2010) Georgia Hatzivassiliou et al.   NATURE

edgeR: a Bioconductor package for differential expression analysis of digital gene expression data

(2009) M. D. Robinson et al.   BIOINFORMATICS